You are here: Industry Insights > regdanvimab

News List

Celltrion Receives CHMP Positive Opinion for regdanvimab (CT-P59) as One of the First Monoclonal Antibodies Recommended as a Treatment for COVID-19 by the CHMP FirstWordPharma
November 12, 2021
Celltrion Group announced today that the European Medicine's Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion recommending marketing...
Inhalon Doses First Patient in Phase 1 Study of Inhaled IN-006 to Treat COVID-19 prnewswire
October 13, 2021
Inhalon Biopharma, Inc., a clinical-stage immunotherapy company developing an inhaled "muco-trapping" antibody platform for treating acute respiratory infections, today announced that...
Celltrion gets priority review in Canada for Covid-19 drug regdanvimab pharmaceutical-technology
August 03, 2021
Health Canada has granted priority review to Celltrion Healthcare’s experimental monoclonal antibody, regdanvimab (CT-P59), for the treatment of Covid-19.
Inhalon Collaborates with Celltrion, Inc. to Develop Nebulized Form of Regdanvimab to Treat COVID-19 Patients at Home prnewswire
July 23, 2021
Inhalon Biopharma today announced it is partnering with Celltrion, Inc. to develop IN-006, an inhaled form of regdanvimab, for treating patients with COVID-19.
Celltrion says its COVID-19 antibody shows ‘strong neutralising activity’ against Delta variant pharmatimes
July 21, 2021
Celltrion has announced that its COVID-19 antibody treatment regdanvimab has a ‘strong neutralising effect’ against the Delta variant first identified in India.
Celltrion’s monoclonal antibody treatment for COVID-19 works against Delta variant: Study expresspharma
July 19, 2021
Regdanvimab (CT-P59) also retained its neutralisation potency against the Lambda variant (C.37, first identified in Peru) using a pseudo-virus neutralisation assay.
EMA begins review of Celltrion’s antibody data for Covid-19 treatment pharmaceutical-technology
February 26, 2021
The human medicines committee (CHMP) of the European Medicines Agency (EMA) has initiated a rolling review of data on Celltrion’s monoclonal antibody regdanvimab (CT-P59) for Covid-19 treatment.